CDK4/6 inhibitors versus PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: An updated systematic review and network meta-analysis of 28 randomized controlled trials

CDK4/6 inhibitors versus PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: An updated systematic review and network meta-analysis of 28 randomized controlled trials

BackgroundUpdated evidence was required to compare the efficacy and safety of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors and phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) inhibitors for patients with hormone receptor-positive and HER2-nega...

Full description

Bibliographic Details
Main Authors: Hangcheng Xu, Yan Wang, Yiqun Han, Yun Wu, Jiayu Wang, Binghe Xu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Oncology
Subjects:
CDK4/6 inhibitors
PI3K/AKT/mTOR inhibitors
hormone receptor-positive
HER2-negative
metastatic breast cancer
network meta-analysis
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.956464/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.956464/full

Similar Items